Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-09
2011-10-25
Lundgren, Jeffrey S. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08044057
ABSTRACT:
Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure ofwherein the presence of each of R1and R2is optional and R1and R2are each independently selected from alkyl, substituted alkyl, heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, halogen, hydroxy, or amino.
REFERENCES:
patent: 4900727 (1990-02-01), Kattige et al.
patent: 5284856 (1994-02-01), Naik et al.
patent: 5703075 (1997-12-01), Gammill et al.
patent: 2003/0050692 (2003-03-01), Sirhan et al.
patent: WO 90/06921 (1990-06-01), None
He et al., “Relationship Between Mesangial Cell Proliferation and Types I and IV Collagen mRNA Levels In Vitro,”Am. J. Physiol., 269 (Cell Physiol. 38): C554-C562, (1995).
International Search Report from parent PCT Application No. PCT/US2004/041265, 4 pp., (Apr. 19, 2005).
Rekhter and Gordon, “Cell Proliferation and Collagen Synthesis Are Two Independent Events in Human Atherosclerotic Plaques,”J. Vasc. Res., 31: 280-286, (1994).
Blume-Jensen and Hunter, “Oncogenic kinase signaling,”Nature411:355-365, May 17, 2001.
Brunn et al., “Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002,”The EMBO Journal15(19):5256-5267, 1996.
Castedo et al., “Mammalian Target of Rapamycin (mTOR): Pro- and Anti-Apoptotic,”Cell Death and Differentiation2002 9:99-100, 2002.
Cohen, “Protein kinases—major drug targets of the twenty-first century?”Nature Reviews1:309-315, Apr. 2002.
Dancey and Sausville, “Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment,”Nature2:296-311, Apr. 2003.
Davies et al., “Specificity and mechanism of action of some commonly used protein kinase inhibitors,”Biochem. J.351:95-105, 2000.
Ding et al., “Antagonists of Phosphatidylinositol 3-Kinase Block Activation of Several Novel Protein Kinases in Neutrophils,”J. Biological Chemistry270(19):11684-11691, 1995.
El-Kholy et al., “The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks Kvcurrents via a direct mechanism,”The FASEB Journal17:720-722, Apr. 2003.
Grünwald et al., “Inhibitors of mTOR Reverse Doxorubicin Resistance Conferred by PTEN Status in Prostate Cancer Cells,”Cancer Research62:6141-6145, Nov. 1, 2002.
Hu et al., “Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models,”Cancer Research62(4):1087-1092, Feb. 15, 2002.
Kozma and Thomas, “Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K,”BioEssays24:65-71 (2002).
Majewski et al., “Immunosuppressive TOR Kinase Inhibitor Everolimus (RAD) Suppresses Growth of Cells Derived from Posttransplant Lymphoproliferative Disorder at Allograft-Protecting Doses,” 75(10):1710-1717, May 27, 2003.
Raught et al., “The target of rapamycin (TOR) proteins,”PNAS98(13):7037-7044, Jun. 19, 2001.
Shegogue et al., “Collagen mRNA Stability is Regulated by mTOR vin a P13-Kinase Independent Pathway,”Molecular Biology of the Cell12(suppl):325a, Nov. 2001.
Vivanco et al., “The Phosphatidylinositol 3-Kinase-AKT Pathway in Human Cancer,”Nature Reviews2:489-501 (Jul. 2002).
Vlahos et al., “A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002),”J. Biological Chemistry269(7):5241-5248, Feb. 18, 1994.
“Novel method of immunosuppression,” IRC Cyprus, Ref. 7918, Sep. 16, 2002, http://www.technology.org.cy/hephaestus/hephaestus.asp?det=yes&what=2324 printed Sep. 10, 2003, 1 page.
Mazzei et al., “N,N-Dialkylaminosubstituded Chromones and Isoxazoles as Potential Anti-inflammatory Agents,”IL Farmaco54:452-460 (1999).
Smith et al., “Functional Up-regulation of HERG K+Channels in Neoplastic Hematopoietic Cells,”The Journal of Biological Chemistry277 (21): 18528-18534 (May 24, 2002).
Kristof Arnold
Moss Joel
Blakely, III Nelson
Klarquist & Sparkman, LLP
Lundgren Jeffrey S.
The United States of America as represented by the Secretary of
LandOfFree
Methods for suppressing an immune response or treating a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for suppressing an immune response or treating a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for suppressing an immune response or treating a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301194